@article{1560f0aad0b842b1a54ad60869c1030a,
title = "Communicating mild cognitive impairment diagnoses with and without amyloid imaging",
abstract = "Background: Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. Methods: We convened a workgroup to formulate recommendations for clinicians providing care to MCI patients. Results: Clinicians should use the MCI diagnosis to validate patient and family concerns and educate them that the patient's cognitive impairment is not normal for his or her age and education level. The MCI diagnosis should not be used to avoid delivering a diagnosis of dementia. For patients who meet Appropriate Use Criteria after standard-of-care clinical workup, amyloid imaging may position specialists to offer more information about etiology and prognosis. Clinicians must set appropriate expectations, including ensuring that patients and families understand the limitations of amyloid imaging. Communication of negative results should include that patients remain at elevated risk for dementia and that negative scans do not indicate a specific diagnosis or signify brain health. Positive amyloid imaging results should elicit further monitoring and conversations about appropriate advance planning. Clinicians should offer written summaries, including referral to appropriate social services. Conclusions: In patients with MCI, there is a need to devote considerable time and attention to patient education and shared decision-making. Amyloid imaging may be a tool to aid clinicians. Careful management of patient expectations and communication of scan results will be critical to the appropriate use of amyloid imaging information.",
keywords = "Amyloid imaging, Diagnosis, Disclosure, Mild cognitive impairment, Prognosis",
author = "Grill, {Joshua D.} and Apostolova, {Liana G.} and Szofia Bullain and Burns, {Jeffrey M.} and Cox, {Chelsea G.} and Malcolm Dick and Dean Hartley and Claudia Kawas and Sarah Kremen and Jennifer Lingler and Lopez, {Oscar L.} and Mark Mapstone and Aimee Pierce and Gil Rabinovici and Roberts, {J. Scott} and Sajjadi, {Seyed Ahmad} and Edmond Teng and Jason Karlawish",
note = "Funding Information: A workgroup meeting was funded by a “ChangeAGEnts” grant from the American Federation for Aging Research and the Hartford Foundation. The funding application outlined the meeting agenda, participants, and topics for discussion. The agenda was further developed through teleconferences among a subset of participants prior to the in-person meeting. Funding Information: JDG has served as an investigator on studies sponsored by Eli Lilly & Company, Biogen Idec, and the Alzheimer{\textquoteright}s Disease Cooperative Study. LGA serves on the Speaker Bureau for Piramal, Inc. and Eli Lilly; is an Advisory Board Member for Eli Lilly; and has received research funding from General Electric Healthcare. JMB receives or has received research support in the last 2 years for clinical trials from Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, and Biogen. SK receives research support from Biogen Idec and Eli Lilly & Company; and receives royalties from UpToDate. JL has provided consultation to Eli Lilly & Company; received research support from Avid Radiopharmaceuticals; and her work on this project has been supported in part by NIH grants P50 AG05133 (Principal Investigator: OLL) and R01 AG046906-01 (Principal Investigator: JI). OLL has served as consultant for Baxter, Lilly, Grifols, and Lundbeck. MM is listed as an inventor of intellectual property owned by the University of Rochester and Georgetown University related to blood biomarkers of preclinical AD. AP has served as a consultant to Lundbeck. GR has received research support from Avid Radiopharmaceuticals, GE Healthcare, and Piramal Imaging; and consulting or speaking honoraria from Eisai, GE Healthcare, Medscape, Piramal Imaging, Putnam, and Lundbeck. ET owns stock in General Electric and Cerner Corp; and receives research support from Eli Lilly & Co, Merck, Biogen, Roche, and the Alzheimer{\textquoteright}s Therapeutic Research Institute. JK is a co-holder of a license of an Integrated NeuroDegenerative Disease Database developed at the University of Pennsylvania; and receives royalties for “Do We Have a Pill for That: Treating Dementia,” Johns Hopkins University Press. The remaining authors declare that they have no competing interests. Funding Information: This work was funded by a “Beeson ChangeAGEnts” grant (JDG, LGA, JK), available to previous recipients of the Paul B. Beeson Emerging Leaders Career Development Award in Aging and funded by the American Federation for Aging Research and the Hartford Foundation. The sponsor had no role in the design of the meeting or the generation of the summary manuscript. JDG is supported by NIA AG016573 and UL1 TR000153. JL and OLL are supported by AG05133. JSR is supported by NIH grant P30 AG053760. SK and ET are supported by the Sidell-Kagan Foundation. Publisher Copyright: {\textcopyright} 2017 The Author(s).",
year = "2017",
month = may,
day = "4",
doi = "10.1186/s13195-017-0261-y",
language = "English (US)",
volume = "9",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",
}